American society of clinical oncology 2008 clinical practice guideline update: Use of chemotherapy and radiation therapy protectants

Journal of Clinical Oncology

Volumn 27, Issue 1, 2009, Pages 127-145

  Hensley, Martee L ^a   Hagerty, Karen L ^a   Kewalramani, Tarun ^a   Green, Daniel M ^a   Meropol, Neal J ^a   Wasserman, Todd H ^a   Cohen, Gary I ^a   Emami, Bahman ^a   Gradishar, William J ^a   Brian Mitchell, R ^a   Thigpen, J Tate ^a   Trotti, Andy ^a   Von Hoff, Daniel ^a   Schuchter, Lynn M ^a  

^a AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMIFOSTINE; ANTHRACYCLINE; BUSULFAN; CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DOXORUBICIN; EPIRUBICIN; ETOPOSIDE; GEMCITABINE; IFOSFAMIDE; MELPHALAN; MESNA; METHOTREXATE; PACLITAXEL; PALIFERMIN; PLACEBO; PLATINUM; RADIOSENSITIZING AGENT; RAZOXANE; TOPOTECAN; VINCRISTINE;

ACUTE TOXICITY; ALLOGENIC BONE MARROW TRANSPLANTATION; ARTICLE; AUTOLOGOUS STEM CELL TRANSPLANTATION; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CANCER STAGING; CHRONIC TOXICITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISEASE ASSOCIATION; DRUG MEGADOSE; DYSPHAGIA; ESOPHAGITIS; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; GRAFT VERSUS HOST REACTION; HEAD AND NECK CANCER; HEARING LOSS; HEMATOLOGIC MALIGNANCY; HUMAN; HYPOTENSION; LUNG NON SMALL CELL CANCER; MEDICAL SOCIETY; METASTASIS; MUCOSA INFLAMMATION; MYELOABLATIVE CONDITIONING; NAUSEA; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NEUTROPENIA; OTOTOXICITY; OVARY CANCER; PARESTHESIA; PATIENT MONITORING; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROTECTION; SALURESIS; SENSORY NEUROPATHY; SIDE EFFECT; SINGLE DRUG DOSE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UROTHELIAL TOXICITY; VOMITING; WALKING DIFFICULTY; WEAKNESS; WHOLE BODY RADIATION; WRITING; XEROSTOMIA;

AMIFOSTINE; ANTINEOPLASTIC AGENTS; FIBROBLAST GROWTH FACTOR 7; HUMANS; MESNA; NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; RADIATION-PROTECTIVE AGENTS; RAZOXANE;

EID: 58149335531     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2008.17.2627     Document Type: Article

References (50)

1. Antonadou D, Pepelassi M, Synodinou M, et al: Prophylactic use of amifostine to prevent radiochemotherapy-induced mucositis and xerostomia in head-and-neck cancer. Int J Radiat Oncol Biol Phys 52:739-747, 2002
2. Antonadou D, Throuvalas N, Petridis A, et al: Effect of amifostine on toxicities associated with radiochemotherapy in patients with locally advanced non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 57:402-408, 2003
3. Bernstein ML, Devidas M, Lafreniere D, et al: Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group phase II study 9457-A report from the Children's Oncology Group. J Clin Oncol 24:152-159, 2006
4. Gold MA, Walker JL, Berek JS, et al: Amifostine pretreatment for protection against topotecan-induced hematologic toxicity: Results of a multicenter phase III trial in patients with advanced gynecologic malignancies. Gynecol Oncol 90:325-330, 2003
5. Hwang WY, Koh LP, Ng HJ, et al: A randomized trial of amifostine as a cytoprotectant for patients receiving myeloablative therapy for allogeneic hematopoietic stem cell transplantation. Bone Mar row Transplant 34:51-56, 2004
6. Kanat O, Evrensel T, Baran I, et al: Protective effect of amifostine against toxicity of paclitaxel and carboplatin in non-small cell lung cancer: A single center randomized study. Med Oncol 20:237-245, 2003
7. Komaki R, Lee JS, Milas L, et al: Effects of amifostine on acute toxicity from concurrent chemotherapy and radiotherapy for inoperable non-small-cell lung cancer: Report of a randomized comparative trial. Int J Radiat Oncol Biol Phys 58: 1369-1377, 2004
8. Leong SS, Tan EH, Fong KW, et al: Randomized double-blind trial of combined modality treatment with or without amifostine in unresectable stage III non-small-cell lung cancer. J Clin Oncol 21:1767-1774, 2003
9. Lorusso D, Ferrandina G, Greggi S, et al: Phase III multicenter randomized trial of amifostine as cytoprotectant in first-line chemotherapy in ovarian cancer patients. Ann Oncol 14:1086-1093, 2003
10. Movsas B, Scott C, Langer C, et al: Randomized trial of amifostine in locally advanced non-small-cell lung cancer patients receiving chemotherapy and hyperfractionated radiation: Radiation therapy oncology group trial 98-01. J Clin Oncol 23:2145-2154, 2005
11. Spencer A, Horvath N, Gibson J, et al: Prospective randomised trial of amifostine cytoprotection in myeloma patients undergoing high-dose melphalan conditioned autologous stem cell transplantation. Bone Marrow Transplant 35:971-977, 2005
12. De Vos FY, Bos AM, Schaapveld M, et al: A randomized phase II study of paclitaxel with carboplatin +/- amifostine as first line treatment in advanced ovarian carcinoma. Gynecol Oncol 97:60-67, 2005
13. Veerasam V, Phromratanapongse P, Suntornpong N, et al: Effect of amifostine to prevent radiotherapy-induced acute and late toxicity in head and neck cancer patients who had normal or mild impaired salivary gland function. J Med Assoc Thai 89:2056-2067, 2006
14. Glover D, Ibrahim J, Kirkwood J, et al: Phase II randomized trial of cisplatin and WR-2721 versus cisplatin alone for metastatic melanoma: An Eastern Cooperative Oncology Group Study (E1686). Melanoma Res 13:619-626, 2003
15. Hilpert F, Stahle A, Tome O, et al: Neuro-protection with amifostine in the first-line treatment of advanced ovarian cancer with carboplatin/paclitaxel- based chemotherapy A double-blind, placebo-controlled, randomized phase II study from the Arbeitsgemeinschaft Gynakologische Onkologoie (AGO) Ovarian Cancer Study Group. Support Care Cancer 13:797-805, 2005
16. Albers J, Chaudhry V, Cavaletti G, et al: Inter ventions for preventing neuropathy caused by cis platin and related compounds. Cochrane Database Syst Rev 1 :CD005228, 2007
17. Jellema AP, Slotman BJ, Muller MJ, et al: Radiotherapy alone, versus radiotherapy with amifostine 3 times weekly, versus radiotherapy with amifostine 5 times weekly: A prospective randomized study in squamous cell head and neck cancer. Cancer 107:544-553, 2006
18. Wasserman TH, Brizel DM, Henke M, et al: Influence of intravenous amifostine on xerostomia, tumor control, and survival after radiotherapy for head-and- neck cancer: 2-year follow-up of a prospective, randomized, phase III trial. Int J Radiat Oncol Biol Phys 63:985-990, 2005
19. Buentzel J, Micke O, Adamietz IA, et al: Intravenous amifostine during chemoradiotherapy for head-and-neck cancer: A randomized placebo-controlled phase III study. Int J Radiat Oncol Biol Phys 64:684-691, 2006
20. Vacha P, Fehlauer F, Mahlmann B, et al: Randomized phase III trial of postoperative radiochemotherapy +/- amifostine in head and neck cancer. Is there evidence for radioprotection? Strahlenther Onkol 179:385-389, 2003
21. Braaksma M, Levendag P: Tools for optimal tissue sparing in concomitant chemoradiation of advanced head and neck cancer: Subcutaneous amifostine and computed tomography-based target delineation. Semin Oncol 29:63-70, 2002
22. Stokman MA, Spijkervet FK, Boezen HM, et al: Preventive intervention possibilities in radiotherapy- and chemotherapy-induced oral mucositis: Results of meta-analyses. J Dent Res 85:690-700, 2006
23. Worthington HV, Clarkson JE, Eden OB: Interventions for preventing oral mucositis for patients with cancer receiving treatment. Cochrane Data base Syst Rev 1: CD003807, 2006
24. Sasse AD, Clark LG, Sasse EC, et al: Amifostine reduces side effects and improves complete response rate during radiotherapy: Results of a meta-analysis. Int J Radiat Oncol Biol Phys 64:784- 791, 2006
25. Mell LK, Malik R, Komaki R, et al: Effect of amifostine on response rates in locally advanced non-small-cell lung cancer patients treated on randomized controlled trials: A meta-analysis. Int J Radiat Oncol Biol Phys 68:111-118, 2007
26. Senzer N: A phase III randomized evaluation of amifostine in stage IIIA/IIIB non-small cell lung cancer patients receiving concurrent carboplatin, paclitaxel, and radiation therapy followed by gemcitabine and cisplatin intensification: Preliminary findings. Semin Oncol 29:38-41, 2002
27. Antonadou D, Coliarakis N, Synodinou M, et al: Randomized phase III trial of radiation treatment +/- amifostine in patients with advanced-stage lung cancer. Int J Radiat Oncol Biol Phys 51:915-922, 2001
28. Koukourakis MI, Kyrias G, Kakolyris S, et al: Subcutaneous administration of amifostine during fractionated radiotherapy: A randomized phase II study. J Clin Oncol 18:2226-2233, 2000
29. Bardet E, Martin L, Calais G, et al: Preliminary data of the GORTEC 2000-02 phase III trial comparing intravenous and subcutaneous administration of amifostine for head and neck tumors treated by external radiotherapy. Semin Oncol 29:57-60, 2002
30. Kouloulias VE, Kouvaris JR, Pissakas G, et al: Phase II multicenter randomized study of amifostine for prevention of acute radiation rectal toxicity: Topical intrarectal versus subcutaneous application. Int J Radiat Oncol Biol Phys 62:486-493, 2005
31. Kouloulias VE, Kouvaris JR, Pissakas G, et al: A phase II randomized study of topical intrarectal administration of amifostine for the prevention of acute radiation-induced rectal toxicity. Strahlenther Onkol 180:557-562, 2004
32. Rades D, Fehlauer F, Bajrovic A, et al: Serious adverse effects of amifostine during radiotherapy in head and neck cancer patients. Radiother Oncol 70:261-264, 2004
33. Bellm LA, Epstein JB, Rose-Ped A, et al: Patient reports of complications of bone marrow transplantation. Support Care Cancer 8:33-39, 2000
34. Sonis ST, Oster G, Fuchs H, et al: Oral mucositis and the clinical and economic outcomes of hematopoietic stem-cell transplantation. J Clin On col 19:2201-2205, 2001
35. Miller AB, Hoogstraten B, Staquet M, et al: Reporting results of cancer treatment. Cancer 47: 207-214, 1981
36. Trotti A, Byhardt R, Stetz J, et al: Common Toxicity Criteria version 2.0: An improved reference for grading the acute effects of cancer treatment: Impact on radiotherapy. Int J Radiat Oncol Biol Phys 47:13-47, 2000
37. Sonis ST, Eilers JP, Epstein JB, et al: Validation of a new scoring system for the assessment of clinical trial research of oral mucositis induced by radiation or chemotherapy: Mucositis Study Group. Cancer 85:2103-2113, 1999
38. Spielberger R, Stiff P, Bensinger W, et al: Palifermin for oral mucositis after intensive therapy for hematologic cancers. N Engl J Med 351:2590-2598, 2004
39. Beaven AW, Shea TC: Palifermin: A keratinocyte growth factor that reduces oral mucositis after stem cell transplant for haematological malignancies. Expert Opin Pharmacother 7:2287-2299, 2006
40. Sonis ST, Elting LS, Keefe D, et al: Perspectives on cancer therapy-induced mucosal injury: Pathogenesis, measurement, epidemiology, and consequences for patients. Cancer 100:1995-2025, 2004
41. Rubin JS, Osada H, Finch PW, et al: Purification and characterization of a newly identified growth factor specific for epithelial cells. Proc Natl Acad Sci U S A 86:802-806, 1989
42. Farrell CL, Bready JV, Rex KL, et al: Keratinocyte growth factor protects mice from chemotherapy and radiation-induced gastrointestinal injury and mortality. Cancer Res 58:933-939, 1998
43. Farrell CL, Rex KL, Kaufman SA, et al: Effects of keratinocyte growth factor in the squamous epithelium of the upper aerodigestive tract of normal and irradiated mice. Int J Radiat Biol 75:609-620, 1999
44. Stiff PJ, Emmanouilides C, Bensinger WI, et al: Palifermin reduces patient-reported mouth and throat soreness and improves patient functioning in the hematopoietic stem-cell transplantation setting. J Clin Oncol 24:5186-5193, 2006
45. Blazar BR, Weisdorf DJ, Defor T, et al: Phase 1/2 randomized, placebo-control trial of palifermin to prevent graft-versus-host disease (GVHD) after allo geneic hematopoietic stem cell transplantation (HSCT). Blood 108:3216-3222, 2006
46. Shea T, Kewalramani T, Mun Y, et al: Evaluation of single-dose palifermin to reduce mucositis: Assessment of efficacy and safety in patients (pts) with hematologic malignancies (HM) receiving autologous peripheral blood progenitor cell (PBPC) transplantation. Biol Blood Marrow Transplant 13:79-80, 2007 (abstr217)
47. Rosen LS, Abdi E, Davis ID, et al: Palifermin reduces the incidence of oral mucositis in patients with metastatic colorectal cancer treated with fluorouracil-based chemotherapy. J Clin Oncol 24: 5194-5200, 2006
48. Meropol NJ, Somer RA, Gutheil J, et al: Randomized phase I trial of recombinant human keratinocyte growth factor plus chemotherapy: Potential role as mucosal protectant J Clin Oncol 21:1452-1458, 2003
49. Tebbi CK, London WB, Friedman D, et al: Dexrazoxane-associated risk for acute myeloid leukemia/myelodysplastic syndrome and other secondary malignancies in pediatric Hodgkin's disease. J Clin Oncol 25:493-500, 2007
50. Centers for Medicare and Medicaid Services: 2008 ASP Drug Pricing Files: Payment Allowance Limits for Medicare Part B Drugs, Effective April 1, 2008 through June 30, 2008. Rockville, MD, Centers for Medicare and Medicaid Services, 2008 http://www. cms.hhs.gov/McrPartBDrugAvgSalesPrice/01a- 2008aspfiles.asp#TopOfPage